| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-05-12 | Ergonex Pharma (Switzerland) Pfizer (USA) |
terguride (oral antagonist of 5-HT2B and 5-HT2A (serotonin) receptors) / pulmonary arterial hypertension | commercialization/ distribution other |
See details |
| 2010-05-11 | Addex (Switzerland) Ortho-McNeil-Janssen Pharmaceuticals/J&J (USA) |
ADX71149 (mGluR2 positive allosteric modulator-PAM) / anxiety, depression, schizophrenia and Alzheimer's disease | R&D commercialization/ distribution development |
See details |
| 2010-05-11 | Swedish Orphan Biovitrum (Sweden) Biomodels (USA) |
assay for mucositis risk in cancer treatment / mucositis risk in cancer treatment |
R&D |
See details |
| 2010-05-10 | Evotec (Germany) Genentech (USA) |
novel small molecule therapeutics | R&D other |
See details |
| 2010-05-10 | bioMérieux (France) GSK (UK) |
companion test / metastatic melanoma | R&D other |
See details |
| 2010-05-10 | Intercell (Austria) Boehringer Ingelheim Vetmedica (Germany) |
antigens derived from Intercell’s Antigen Identification Program (AIP®) to develop animal vaccines Intercell's AIP® has already been used to identify relevant and protective antigens for several bacterial pathogens including Staphylococcus aureus and epidermidis, Streptococcus pneumoniae, Streptococcus agalactiae and pyogenes, Enterococcus faecalis, Klebsiella pneumoniae, Borrelia spp., ETEC, Shigella, Campylobacter jejuni, non-typable Haemophilus influenzae, and Moraxella catarrhalis. / undisclosed animal diseases |
R&D licensing |
See details |
| 2010-05-07 | SynCo Bio Partners (the Netherlands) OncoMed Pharmaceuticals (USA) |
antibodies | manufacturing |
See details |
| 2010-05-07 | Glenmark (India) Sanofi-Aventis (France) |
vanilloid receptor (TRPV3) antagonist molecules, including a first-in-class clinical compound, GRC 15300. The TRPV3 receptor is an ion channel protein that mediates and influences cell signaling, including the nerve cell signaling that generates some types of pain. Inhibitors of TRPV3 are predicted to be useful in the treatment of inflammation, various pain conditions, and other diseases and disorders. / chronic pain |
R&D licensing commercialization/ distribution marketing/ promotion |
See details |
| 2010-05-06 | Intercell (Austria) Cytos Biotechnology (Switzerland) |
platform technology for monoclonal antibody discovery / infectious diseases with a focus on group B Streptococcus and bacteria involved in hospital acquired infections | other |
See details |
| 2010-05-05 | Micromet (Germany-USA) Boehringer Ingelheim (Germany) |
BiTE® antibody / multiple myeloma | R&D licensing manufacturing commercialization/ distribution development marketing/ promotion |
See details |
| 2010-05-05 | EndoCeutics (Canada) Bayer Schering Pharma (Germany) |
Vaginorm® (intra-vaginal application of dehydroepiandrosterone-DHEA) / vulvovaginal atrophy and female sexual dysfunction in postmenopausal women | licensing manufacturing commercialization/ distribution development marketing/ promotion |
See details |
| 2010-05-04 | Vernalis (UK) Servier (France) |
/ cancer | R&D |
See details |
| 2010-05-04 | Stemgent (USA) Miltenyi Biotec (Germany) |
stem cell research products | commercialization/ distribution development other |
See details |
| 2010-05-03 | Targacept (USA) AstraZeneca (UK) |
TC-5619 (small molecule highly selective for the alpha7 NNR) / attention deficit/hyperactivity disorder (ADHD) Alzheimer's disease cognitive dysfunction in schizophrenia |
licensing commercialization/ distribution development |
See details |
| 2010-05-03 | Epigenomics (Germany) Warnex Medical Laboratories (Canada) |
Septin9 biomarker for colorectal cancer blood test screening / colorectal cancer | licensing |
See details |
